Check the

ARTERIUS LIMITED

Company
ARTERIUS LIMITED (06981739)

ARTERIUS

Phone: 01134 264 300
A⁺ rating

ABOUT ARTERIUS LIMITED

Founded in 2009, Leeds-based Arterius is developing a next-generation bioresorbable cardiovascular scaffold (stent) with an emerging market-leading clinical profile. The founding directors have significant experience in the development of medical devices and in the cardiovascular devices field in particular. The development team is supported by a consortium of experts comprising, amongst others, clinical advisory team; computational design group at Southampton University; polymer process engineering at Bradford University and pre-clinical and clinical institutions. Arterius has recently completed the pre-clinical trials and, on the back of these, believes that this collaboration has delivered a next generation drug eluting fully biodegradable stent with a market leading profile.

MISSION

Arterius was established by Dr Kadem Al-Lamee and Alistair Taylor to exploit opportunities in the $8.1bn coronary stent market. The company has worked in partnership with a consortium of academic contributors consisting of the Computational Design Group at Southampton University, UK; the Industrial Research Centre in Polymer Engineering, Bradford University, UK; and the Department of Surface Characterisation and Drug Distribution at Nottingham University, UK to design, manufacture and put into pre-clinical evaluation a family of novel vascular scaffold stents, under the trademarked name ArterioSorb™.

Product Evolution

Stent technology (including the design, alloy used and strut thickness) developed rapidly in the 1990s. The second generation products appeared in 2000 in response to the continued concerns over restenosis and thrombosis. These stents comprised a BMS which had been coated in anti-proliferative drugs such as paclitaxel (to prevent tissue growth) or anti-inflammatory/immunosuppressive drugs such as sirolimus, everolimus, tacrolimus or dexamethasone (to reduce the inflammation at the site of the stent). These drugs ‘eluted’ over time providing therapeutic concentrations in local tissues but low systemic doses, thus avoiding systemic adverse effects.

Bioresorbable scaffolds (stents) are made from common biopolymers used in medical devices, such as poly(lactic acid (PLA or PLLA), rather than metal. These stents provide mechanical support for a period of time while the artery recovers from the PCI, before dissolving away to leave nothing behind.

The ideal BRS needs to be formed from a polymer that ensures short to mid-term scaffolding of the vessel in order to maintain patency while the vessel heals and remodels. It is still unclear exactly how long a BRS needs to provide a scaffold before full resorption but currently devices resorb after between 6 and 24 months.

There is potential to not only match, but to better the clinical profile of the existing products: Uniquely BRSs, offer the possibility of late lumen gain and enhanced vasomotion. These effects have been observed in early clinical studies. Lower incidence of angina at 1 year after PCI with BRS have also been reported when compared to DES (16% vs 28%, p=0.001). This is likely to be due to expansion of the internal elastic membrane and growth of the lumen as the device begins to dissolve and the vessel is constrained.(Serruys PW, Chevalier B, Dudek D, Cequier A, Carrie D, Iniguez A, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385(9962):43-54.)

KEY FINANCES

Year
2017
Assets
£186.94k ▼ £-27.24k (-12.72 %)
Cash
£108.02k ▼ £-35.63k (-24.80 %)
Liabilities
£173.65k ▲ £67.62k (63.78 %)
Net Worth
£13.3k ▼ £-94.86k (-87.71 %)

REGISTRATION INFO

Company name
ARTERIUS LIMITED
Company number
06981739
Status
Active
Categroy
Private Limited Company
Date of Incorporation
05 Aug 2009
Age - 15 years
Home Country
United Kingdom

CONTACTS

Website
arterius.co.uk
Phones
01134 264 300
Registered Address
25-29 SANDY WAY,
YEADON,
LEEDS,
LS19 7EW

ECONOMIC ACTIVITIES

72190
Other research and experimental development on natural sciences and engineering

LAST EVENTS

31 Mar 2017
Statement of capital following an allotment of shares on 26 February 2017 GBP 2,876
30 Mar 2017
Amended total exemption small company accounts made up to 31 August 2016
26 Sep 2016
Total exemption small company accounts made up to 31 August 2016

See Also


Last update 2018

ARTERIUS LIMITED DIRECTORS

Alistair Henderson Taylor

  Acting
Appointed
05 August 2009
Role
Secretary
Address
Corpus Christi House. 9, West Street, Godmanchester, Cambs, United Kingdom, PE29 2HY
Name
TAYLOR, Alistair Henderson

Kadem Al Lamee

  Acting PSC
Appointed
05 August 2009
Occupation
Chief Executive
Role
Director
Age
74
Nationality
British
Address
64 Broomfield, Adel, Leeds, West Yorkshire, LS16 7AD
Country Of Residence
United Kingdom
Name
AL-LAMEE, Kadem
Notified On
6 April 2016
Nature Of Control
Ownership of shares – More than 25% but not more than 50%

Peter James Mason

  Acting
Appointed
24 March 2015
Occupation
Company Director
Role
Director
Age
50
Nationality
British
Address
61 Richmond Avenue, London, England, N1 0LX
Country Of Residence
United Kingdom
Name
MASON, Peter James

Jaka Plut

  Acting
Appointed
10 April 2014
Occupation
Company Director
Role
Director
Age
42
Nationality
Slovene
Address
57 Kosenice, Novo Mesto, Slovenia
Country Of Residence
Slovenia
Name
PLUT, Jaka

Alistair Henderson Taylor

  Acting
Appointed
05 August 2009
Occupation
Executive Chairman
Role
Director
Age
83
Nationality
British
Address
Corpus Christi House, West Street, Godmanchester, Huntingdon, Cambridgeshire, PE29 2HY
Country Of Residence
England
Name
TAYLOR, Alistair Henderson

Dusan Plut

  Resigned
Appointed
25 November 2010
Resigned
10 April 2014
Occupation
Company Director
Role
Director
Age
69
Nationality
Slovenian
Address
25-29, Sandy Way, Yeadon, Leeds, United Kingdom, LS19 7EW
Country Of Residence
Slovenia
Name
PLUT, Dusan

REVIEWS


Check The Company
Excellent according to the company’s financial health.